PointState Capital’s Impax Laboratories, Inc. IPXL Stock Holding History

PointState Capital’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-73,100	Closed	-$1.48M	–	203
2017 Q3	$1.48M	Buy	+73,100	New	+$1.4M	0.01%	142
2017 Q2	–	Sell	-970,400	Closed	-$12.3M	–	189
2017 Q1	$12.3M	Buy	+970,400	New	+$11.7M	0.13%	91
2016 Q1	–	Sell	-300,000	Closed	-$12.8M	–	126
2015 Q4	$12.8M	Buy	+300,000	New	+$12M	0.33%	44
2015 Q1	–	Sell	-300,000	Closed	-$9.5M	–	159
2014 Q4	$9.5M	Buy	300,000 +150,000	+100%	+$4.39M	0.16%	83
2014 Q3	$3.56M	Sell	150,000 -350,000	-70%	-$8.97M	0.06%	80
2014 Q2	$15M	Buy	500,000 +150,000	+43%	+$4.05M	0.19%	68
2014 Q1	$9.25M	Buy	+350,000	New	+$8.75M	0.15%	74
2013 Q3	–	Sell	-250,000	Closed	-$4.99M	–	175
2013 Q2	$4.99M	Buy	+250,000	New	+$4.44M	0.09%	105

Other funds holding IPXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCW Group Los Angeles, California $14.9B AUM 46.29% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

PointState Capital's IPXL Position: Q4 2017 in Review

PointState Capital sold out of Impax Laboratories, Inc. (IPXL) in Q4 2017, closing a stake of 73,100 shares — an estimated $1.48M sold.

PointState Capital first reported a position in IPXL in Q2 2013 and held it in 8 quarters. The position peaked at $15M in Q2 2014. 200 funds tracked by Wall St. Rank hold IPXL as of Q4 2017.

PointState Capital reported no remaining Impax Laboratories, Inc. position as of Q4 2017 after selling out during the quarter.
PointState Capital sold 73,100 Impax Laboratories, Inc. shares in Q4 2017, an estimated $1.48M.
PointState Capital first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 8 quarters.
PointState Capital's Impax Laboratories, Inc. position peaked at $15M in Q2 2014.
200 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2017.

Based on PointState Capital's 13F filing for Q4 2017, filed 14 Feb 2018.